Back

The RNA-binding protein Imp1 promotes a Spdef transcriptional program and mucus fucosylation during necrotizing enterocolitis

Swift, K. A.; Shumway, A. J.; Aloia, M.; Hedges, M.; Pung, R.; Rodriguez Santiago, C.; Shanahan, M. T.; Drake, A.; Hakar, M. H.; Selesner, L.; Kuhn, M.; Yung, C.; Sethupathy, P.; Andres, S. F.

2026-01-31 molecular biology
10.64898/2026.01.30.702645 bioRxiv
Show abstract

BackgroundIn the United States over 10% of all neonates are born premature (less than 37 weeks gestational age), and many face complications related to prematurity, including necrotizing enterocolitis (NEC). NEC is the most deadly gastrointestinal disease and the leading cause of death in preterm neonates, with up to 50% mortality. Since there is no cure for NEC, prevention is the best strategy. Enhancing our understanding of intestinal epithelial cell (IEC) responses to NEC damage will provide novel therapeutic targets to prevent NEC. Published evidence suggests that the RNA-binding protein insulin-like growth factor 2 mRNA binding protein 1 (IMP1) plays roles in intestinal development, barrier function, and intestinal repair. Notably, however, roles for IMP1 in NEC are not defined. Goblet cells produce protective mucus in the intestine, and their mature function is dependent on the transcription factor Spdef. Emerging evidence suggests that goblet cell mucus complexity impacts barrier function and inflammation susceptibility. This study aimed to define the role of IMP1 in NEC pathogenesis using neonatal human enteroids and a model of NEC-like intestinal injury in mice with IEC-specific Imp1 overexpression and loss. HypothesisIMP1 expression is protective in NEC. MethodsThis study used mice with intestinal epithelial Imp1 overexpression or loss and corresponding wild-type controls. At post-natal day 3, mice of both sexes were randomly assigned to control or NEC groups. NEC was induced with the well-established experimental NEC-like intestinal injury model that includes stress, formula feeding, and hypoxia. Imp1 effects on experimental NEC were assessed using RNA sequencing, western blotting, and immunostaining. ResultsInflammatory bacteria induced IMP1 expression in neonatal human enteroids. Mice with Imp1 overexpression incur worse intestinal damage during NEC. Pathway analysis of RNA sequencing data revealed a significant enrichment of the Spdef transcriptional network in Imp1IEC-OE during NEC. This included significant upregulation of Spdef target genes such as Agr2 (in NEC WT: 617.8 {+/-} 33.56 vs Imp1IEC-OE: 812.9 {+/-} 111.3, p=0.02) and Fut2 (in NEC WT: 219.4 {+/-} 34 vs Imp1IEC-OE: 396.6 {+/-} 62.9, p=0.05). In silico analysis predicted Imp1 binding to Spdef and mucus glycosylation mediator mRNAs. Although genotype did not affect goblet cell number, Imp1IEC-OE mice with NEC exhibited significant increases (p0.05) in Spdef protein, genes responsible for goblet cell function (Spink4, Klk1, Tspg1) and mucus glycosylation (Gcnt3, B3gnt7, Qsox1). Ultimately, Imp1 overexpression led to increased mucus fucosylation during NEC. ConclusionOur data indicate that during NEC, upregulation of Imp1 promotes goblet cell function via Spdef, including enhanced goblet cell maturation and mucus fucosylation. NEW AND NOTEWORTHYExpression of the RNA-binding protein Imp1 is enhanced in neonatal human enteroids in response to inflammatory bacteria. Imp1 regulates goblet cell function in response to early intestinal inflammation in a mouse model of necrotizing enterocolitis. Specifically, Imp1 promotes a Spdef transcriptional program by upregulating Spdef, resulting in elevated gene expression of Spdef target genes. Additionally, Imp1 increases the gene expression of (1,2)fucosyltransferase, Fut2, and subsequently, production of fucosylated mucus marked by UEA1. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=178 SRC="FIGDIR/small/702645v1_ufig1.gif" ALT="Figure 1"> View larger version (63K): org.highwire.dtl.DTLVardef@189f615org.highwire.dtl.DTLVardef@7aeeedorg.highwire.dtl.DTLVardef@dc258corg.highwire.dtl.DTLVardef@1252b98_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 16 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 21%
8.8%
2
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.1%
8.8%
3
American Journal of Physiology-Gastrointestinal and Liver Physiology
11 papers in training set
Top 0.1%
4.1%
4
Frontiers in Immunology
586 papers in training set
Top 2%
3.7%
5
International Journal of Molecular Sciences
453 papers in training set
Top 2%
3.7%
6
Cells
232 papers in training set
Top 0.8%
3.2%
7
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.2%
2.2%
8
Mucosal Immunology
42 papers in training set
Top 0.1%
2.2%
9
The FASEB Journal
175 papers in training set
Top 0.7%
2.0%
10
Biology Open
130 papers in training set
Top 0.7%
2.0%
11
Scientific Reports
3102 papers in training set
Top 56%
1.8%
12
JCI Insight
241 papers in training set
Top 3%
1.7%
13
Nutrients
64 papers in training set
Top 0.9%
1.7%
14
ACS Omega
90 papers in training set
Top 2%
1.5%
15
Molecular Neurobiology
50 papers in training set
Top 0.4%
1.5%
16
Gastroenterology
40 papers in training set
Top 1%
1.3%
50% of probability mass above
17
Placenta
18 papers in training set
Top 0.1%
1.3%
18
Glia
74 papers in training set
Top 0.4%
1.2%
19
Inflammatory Bowel Diseases
15 papers in training set
Top 0.2%
0.9%
20
Human Molecular Genetics
130 papers in training set
Top 3%
0.9%
21
Molecular Psychiatry
242 papers in training set
Top 3%
0.8%
22
eLife
5422 papers in training set
Top 54%
0.8%
23
Genes
126 papers in training set
Top 2%
0.8%
24
Viruses
318 papers in training set
Top 5%
0.8%
25
Frontiers in Physiology
93 papers in training set
Top 5%
0.8%
26
Wellcome Open Research
57 papers in training set
Top 2%
0.8%
27
The FEBS Journal
78 papers in training set
Top 0.9%
0.7%
28
Biology
43 papers in training set
Top 3%
0.7%
29
iScience
1063 papers in training set
Top 32%
0.7%
30
Journal of Cystic Fibrosis
15 papers in training set
Top 0.2%
0.7%